← Back to headlines
REDUCE-IT Legacy Analysis Shows Persistent Cardiovascular Benefits After Treatment Cessation
New data presented at the European Society of Cardiology Congress 2026 indicates that adherent patients continue to experience cardiovascular benefits even after stopping Icosapent Ethyl treatment. The legacy analysis underscores the long-term impact of the therapy on heart health outcomes.
28 Aug, 12:15 — 28 Aug, 12:15
